Cardiovascular Safety Assessment in Early Phase Clinical Studies

Classic Thorough QT Studies vs. Today's Early Precision QT Studies

OCTOBER 17, 2017

4:30 p.m. – 8:00 p.m. (PDT)


Tel: 650 925-6168

Speaker Bios Abstracts Agenda

Altasciences and iCardiac are pleased to invite you to an exclusive complimentary scientific symposium which is designed for members of the Pharmaceutical and Biopharmaceutical communities, to openly discuss and share ideas on Early Cardiac Assessment and Thorough QT studies.

Join us as industry experts share their in-depth knowledge on the following topics:

  • Benefits of Early Cardiac Safety Assessment
  • Novel approaches to QT and TQT Studies
  • Recent regulatory ICH E14 revisions
  • Impact of technological advancements

Who Should Attend?

  • Drug development teams
  • Clinical Operations
  • Outsourcing professionals
  • ECG safety data managers
  • Industry management
  • Clinical project managers
  • Regulatory specialists
  • Safety assessment personnel

If you have any questions about this symposium or would like information on obtaining a certificate of completion, please contact Nathalie Poirier at or call 450 973‑3155 ext. 2238.


October 17, 2017

  • Cocktails and hors d’oeuvres

  • Introduction

    Archana Sah, Clinical Operations Executive

    Archana Sah's bio »

  • Recent regulatory ICH E14 revisions regarding QT assessment and its impact on Thorough QT studies

    Presented by Borje Darpo, MD, PhD, Chief Scientific Officer, iCardiac

  • How innovative technology has transformed Thorough QT studies over the last decade

    Presented by Graham Wood, PhD, Executive Vice President, Phase I Clinical Development, Altasciences

  • Cardiovascular toxicity evaluation in oncology clinical development

    Presented by Gregory K. Reid, MSc, MBA, Director, Medical Science Liaison, Altasciences

  • Networking Session - Cocktails and hors d’oeuvres